(Q40005203)

16 September 2017

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells (English)

1 reference

16 September 2017

1 reference

4

Keith T Flaherty

1 reference

16 September 2017

5

Dagmar Kulms

1 reference

16 September 2017

7

Claus Garbe

1 reference

16 September 2017

6

Evelyn Maczey

1 reference

16 September 2017

Konstantinos G Lasithiotakis

1

1 reference

16 September 2017

Tobias W Sinnberg

2

1 reference

16 September 2017

Birgit Schittek

3

1 reference

16 September 2017

Friedegund E Meier

8

1 reference

16 September 2017

language of work or name

English

0 references

publication date

6 March 2008

1 reference

Journal of Investigative Dermatology

16 September 2017

1 reference

16 September 2017

128

1 reference

16 September 2017

2013-2023

1 reference

16 September 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/jid.2008.44

16 September 2017

0 references

cites work

Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

When translation meets transformation: the mTOR story

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

The role of Bcl-2 family members in the progression of cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Chemotherapy and targeted therapy combinations in advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Evidence for cyclin D3 as a novel target of rapamycin in human T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Recent Trends in Cutaneous Melanoma Incidence Among Whites in the United States

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

B-RAF is a therapeutic target in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Predicted mechanisms of resistance to mTOR inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Akt-regulated pathways in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Human melanoma progression in skin reconstructs : biological significance of bFGF.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Activation of extracellular signal-regulated kinases ERK1 and ERK2 induces Bcl-xL up-regulation via inhibition of caspase activities in erythropoietin signaling

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

New techniques for the in vitro culture of human skin keratinocytes and perspectives on their use for grafting of patients with extensive burns

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Effects of rapamycin on cardiac and skeletal muscle contraction and crossbridge cycling

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Cyclin-dependent kinase-5 prevents neuronal apoptosis through ERK-mediated upregulation of Bcl-2.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

TOR signaling in growth and metabolism

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

A fluorometric rapid microassay to identify anti-proliferative compounds for human melanoma cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.44

7 January 2021

Identifiers

DOI

10.1038/JID.2008.44

1 reference

16 September 2017

1 reference